PROTECTIVE ACTIVITY OF VI CAPSULAR POLYSACCHARIDE VACCINE AGAINST TYPHOID FEVER

The Lancet

Volumn 330, Issue 8569, 1987, Pages 1165-1169

  Klugman, KeithP ^{a,b,c,d,e,f,g}   Koornhof, HendrikJ ^{a,b,c,d,e,f,g}   Schneerson, Rachel ^{a,b,c,d,e,f,g}   Cadoz, Michel ^{a,b,c,d,e,f,g}   Gilbertson, IanT ^{a,b,c,d,e,f,g}   Robbins, JohnB ^{a,b,c,d,e,f,g}   Schulz, Dominique ^{a,b,c,d,e,f,g}   Armand, Jacques ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b National Institute for Tropical Diseases ^*  (United Kingdom)

^c SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^d Department of National Health and Population Development ^*  (United Kingdom)

^e UNIVERSITY OF PRETORIA   (South Africa)

^f Institut Merieux   (France)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TYPHOID VACCINE;

CHILD; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PREVENTION; RANDOMIZED CONTROLLED TRIAL; TYPHOID FEVER; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; PILOT PROJECTS; POLYSACCHARIDES, BACTERIAL; RADIOIMMUNOASSAY; RANDOM ALLOCATION; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINATION;

EID: 0023633872     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(87)91316-X     Document Type: Article

References (35)

1. Selective primary health care: Strategies for control of disease in the developing world. XX. Typhoid fever
2. Typhoid fever-an endemic disease with interhuman transmission
3. The present status of field and laboratory studies of typhoid and paratyphoid vaccines
4. Large scale field trial of Ty21a live oral typhoid vaccine in entenc-coated capsule formulation
5. A new antigen of B typhosus. Its relation to virulence and to active and passive immunisation
6. Typhoid fever. Pathogenesis and immunological control
7. D-Galaktosaminomsaure (2-amino-2-desoxy-D-galakturonsaure) als baustein des Vi-antigens
8. Strukturaufklarung des Vi antigens aus Curobacter freundii 5396-38
9. Studies on Vi antigen. II. Purification of Vi antigen from Escherichia colt 5396-38
10. Re-examination of the protective role of the capsular polysacchande (Vi antigen) of Salmonella typhi
11. Immunochemical properties of Vi antigen from Salmonella typhi Ty 2: Presence of two antigenic determinants
12. Physicochemical and biological properties of sonically treated Vi antigen
13. Vi antigen from Salmonella typhi and immunity against typhoid fever. I. Isolation and immunologic properties m animals
14. Safety and immunogenicity of the Salmonella typhi Vi capsular polysacchande vaccines
15. Typing of typhoid bacilli with Vi bacteriophage. Suggestions for its standardisation
16. A new method for labelling protein hormones with radio-iodine for use in the radioimmunoassay
17. The pathogenic and immunogenic activities of Salmonella typhi in relation to its antigenic constituents
18. Antibody responses to meningococcal polysaccharide vaccines
19. Vaccines against encapsulated bacteria. A global agenda
20. A seven-year field trial of two typhoid vaccines in Guyana
21. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: Three-year results
22. Failures with oral typhoid vaccine Ty21a
23. Inefficacy of the commercial live oral Ty21a vaccine in the prevention of typhoid fever
24. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine
25. Typhoid vaccines
26. Controlled field trial on the effectiveness of one and two doses of acetone-inactivated and dned typhoid vaccine
27. Second attacks of typhoid fever
28. Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by pnmary infection
29. Re-infection with a different Vi-phage type of Salmonella typhi in an endemic area
30. Typhoid fever vaccine—yes or no?
31. A controlled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol-inactivated typhoid vaccines in Yugoslavia
32. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age
33. Kinetics of antibody production to group A and group C meningococcal polysacchande vaccines administered during the first six years of life. Prospects for routine immunization in infants and children
34. Is there a genetic immune defect in families with meningococcal meningitis?
35. Mothers of infants with neonatal group B streptococcal septicaemia are poor responders to bacterial carbohydrate antigens